Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.0K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

96
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
96
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

121
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
121
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

59
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
59
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

80
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
80
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

1.6K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abnormal left ventricular subendocardial perfusion and diastolic function in women with obesity and heart failure and preserved ejection fraction.

The international journal of cardiovascular imaging·2023
Same author

QT Prolongation and In-Hospital Ventricular Arrhythmic Complications in Patients With Apical Ballooning Takotsubo Syndrome.

JACC. Clinical electrophysiology·2022
Same author

Contribution of hemoglobin concentration to cardiorespiratory fitness in black African American patients with recently decompensated heart failure and reduced ejection fraction.

Minerva cardiology and angiology·2022
Same author

Synergistic effect of myocardial injury and mid-regional proAdrenomedullin elevation in determining clinical outcomes of SARS-CoV-2 patients.

Frontiers in medicine·2022
Same author

Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis.

Heart (British Cardiac Society)·2022
Same author

Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications.

EBioMedicine·2022

Related Experiment Video

Updated: Oct 9, 2025

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages
06:52

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages

Published on: May 21, 2018

10.9K

The inflammasome in heart failure.

Eleonora Mezzaroma1,2, Antonio Abbate2, Stefano Toldo2

  • 1Pharmacotherapy and Outcomes Sciences, Virginia Commonwealth University, Richmond, VA, USA.

Current Opinion in Physiology
|December 17, 2021
PubMed
Summary

The NLRP3 inflammasome drives heart failure progression. Inhibiting this inflammasome pathway shows promise for treating heart failure by reducing cardiac remodeling and improving heart function.

Keywords:
Caspase-1Heart FailureInterleukin-18Interleukin-1βNLRP3 Inflammasome

More Related Videos

Visualization of Inflammatory Caspases Induced Proximity in Human Monocyte-Derived Macrophages
08:41

Visualization of Inflammatory Caspases Induced Proximity in Human Monocyte-Derived Macrophages

Published on: April 6, 2022

2.8K
Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
09:04

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells

Published on: May 22, 2014

21.1K

Related Experiment Videos

Last Updated: Oct 9, 2025

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages
06:52

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages

Published on: May 21, 2018

10.9K
Visualization of Inflammatory Caspases Induced Proximity in Human Monocyte-Derived Macrophages
08:41

Visualization of Inflammatory Caspases Induced Proximity in Human Monocyte-Derived Macrophages

Published on: April 6, 2022

2.8K
Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
09:04

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells

Published on: May 22, 2014

21.1K

Area of Science:

  • Immunology
  • Cardiology
  • Molecular Biology

Background:

  • The NACHT, leucine-rich repeat (LRR), and pyrin domain (PYD)-containing protein 3 (NLRP3) inflammasome is a key regulator of inflammatory responses.
  • Dysregulation of the NLRP3 inflammasome and its associated cytokines, IL-1β and IL-18, is implicated in various heart diseases.
  • Growing evidence links NLRP3 inflammasome activity to the pathogenesis and progression of heart failure (HF).

Purpose of the Study:

  • To investigate the role of the NLRP3 inflammasome in heart failure.
  • To evaluate the therapeutic potential of NLRP3 inflammasome inhibition in HF.

Main Methods:

  • Analysis of human samples and experimental animal models of heart failure.
  • Preclinical studies assessing the effects of NLRP3 inhibition on cardiac remodeling and function.
  • Review of early-phase clinical studies on NLRP3 inflammasome pathway blockade in HF patients.

Main Results:

  • Human samples and animal models indicate a causative role for NLRP3 in HF development and progression.
  • Preclinical research demonstrates that NLRP3 inhibition effectively reduces adverse cardiac remodeling and enhances left ventricular function in HF.
  • Early clinical trials confirm the safety and efficacy of blocking the NLRP3 inflammasome pathway.

Conclusions:

  • The NLRP3 inflammasome is a critical mediator in heart failure.
  • Targeting the NLRP3 inflammasome represents a promising therapeutic strategy for managing heart failure.
  • Clinical studies support the potential of NLRP3 inhibition for improving outcomes in HF patients.